Actos bladder cancer
Recent research has shown that if Actos is taken for a long period of time, there will be an improved likelihood of the patient rising actos bladder cancer. Countries like France have removed this drug from the market. In the United States, warning labels are being efficient. But, it is basically the liability of the manufacturer to withdraw the drug right away after any signs of dangerous side effects are found. Still, they fail to do so most likely because of profitable considerations. Bad Track Record of Diabetes Drugs: Severe health complications and different side effects have been reported by people who are using conservative and prescription drugs for the treatment of diabetes. Different research studies have indicated that there is a heightened risk of developing cancer by the enduring use of some diabetes drugs. In particular, an ongoing research covering a period of ten years by a most important pharmaceutical company has indicated that sustained use of Actos increases the risk of bladder cancer. It is an oral prescription drug used specially for treating Type 2 Diabetes mellitus. Pioglitazone is the generic name of Actos and it is part of the drug peroxisome proliferator-activated receptor agonists. A research study connecting 193,000 diabetics was conducted. The data composed showed that the patients who had been use pioglitazone for at least two years statement high number of bladder cancer than the patients who had been using other medication. It was also experiential that the longer the diabetics used this drug; the high was the risk of bladder cancer.